80 / 84
80
placebo-controlled trial. Arthritis Care Res
(Hoboken) 2010;62:1266-71.
55. Braun J, Deodhar A, Inman RD, van der Heijde
D, Mack M, Xu S, Hsu B. Golimumab administered
subcutaneously every 4 weeks in ankylosing
spondylitis: 104-week results of the GO-RAISE
study. Ann Rheum Dis 2012;71:661-7.
56. Marzo-Ortega H, McGonagle D, Jarrett S,
Haugeberg G, Hensor E, O'connor P, et al.
Infliximab in combination with methotrexate in
active ankylosing spondylitis: a clinical and imaging
study. Ann Rheum Dis 2005;64:1568-75.
57. Baraliakos X, Listing J, Brandt J, Haibel H,
Rudwaleit M, Sieper J, et al. Radiographic
progression in patients with ankylosing spondylitis
after 4 yrs of treatment with the anti-TNF-alpha
antibody infliximab. Rheumatology (Oxford)
2007;46:1450-3.
58. van der Heijde D, Landewé R, Baraliakos X,
Houben H, van Tubergen A, Williamson P, et al.
Study for the Evaluation of Recombinant Infliximab
Therapy Study Group. Radiographic findings
following two years of infliximab therapy in
patients with ankylosing spondylitis. Arthritis
Rheum 2008;58:3063-70.
59. van der Heijde D, Landewé R, Einstein S, Ory P,
Vosse D, Ni L, et al. Radiographic progression of
ankylosing spondylitis after up to two years of